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Abstract: For centuries, plants have been exploited by mankind as sources of numerous cancer
chemotherapeutic agents. Good examples of anticancer compounds of clinical significance today
include the taxanes (e.g., taxol), vincristine, vinblastine, and the podophyllotoxin analogues that
all trace their origin to higher plants. While all these drugs, along with the various other available
therapeutic options, brought some relief in cancer management, a real breakthrough or cure has
not yet been achieved. This critical review is a reflection on the lessons learnt from decades of
research on the iridoid glycoside geniposide and its aglycone, genipin, which are currently used
as gold standard reference compounds in cancer studies. Their effects on tumour development
(carcinogenesis), cancer cell survival, and death, with particular emphasis on their mechanisms of
actions, are discussed. Particular attention is also given to mechanisms related to the dual pro-oxidant
and antioxidant effects of these compounds, the mitochondrial mechanism of cancer cell killing
through reactive oxygen species (ROS), including that generated through the uncoupling protein-2
(UCP-2), the inflammatory mechanism, and cell cycle regulation. The implications of various studies
for the evaluation of glycosidic and aglycone forms of natural products in vitro and in vivo through
pharmacokinetic scrutiny are also addressed.
Keywords: cancer; carcinogenesis; metastasis; genipin; geniposide; reactive oxygen species;
apoptosis; uncoupling protein 2
1. Introduction
For generations, plants have been extensively used by mankind to treat a number of diseases,
including cancer. Many exemplary anticancer chemotherapeutic agents of plants origin with distinct
biochemical mechanisms are also in use today. The most popular plant-derived anticancer compounds
of clinical significance include those specifically targeting the cellular microtubule cytoskeleton system
such as the taxanes (e.g., paclitaxel (Taxol) and docetaxel (Taxotere)), vincristine and vinblastine [1].
The dynamic process of microtubule assembly and disassembly involved in diverse cellular processes
such as intracellular transport (e.g., exocytosis), cell division, and cell motility (or migration) could be
hindered by such drugs, leading to cell growth arrest and induction of cell death. Numerous other
drugs of plants origin act through the same mechanism, among which colchicine, combretastatin,
and taccalonolides have been utilized in various forms. Podophyllotoxins and other cancer
chemotherapeutics derived from such structural skeleton (e.g., epipodophyllotoxins including etoposide
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and teniposide) that act by inhibiting topoisomerase II are further remarkable examples of anticancer
drug discoveries based on natural products/plants. Another group of plant-derived therapeutic
agents are the cytotoxic quinoline alkaloids, such as camptothecin, which inhibit topoisomerase I.
Review articles on the mechanism of action of such plant-derived chemotherapeutic agents are widely
available [2,3].
With increased knowledge and understanding of cancer biology, to date, there are numerous
options for cancer therapy. In most cases, solid tumours or solid masses are removed when possible
by surgical means followed by radiotherapy. Chemotherapy, however, remains the most common
therapeutic option, and developments in the last few decades have even added several biological
agents (e.g., trastuzumab (Herceptin) and bevacizumab (Avastin)) [4], although the cost of such
treatments is often beyond the reach of many patients. Hormone and immunotherapy options are
also available. Further development of new drugs for cancer therapy in recent years has not stalled
but rather accelerated. In 2014, it was reported that 771 new agents were in the pipeline, while the
number of new drugs that had received regulatory approval by the Food and Drug Administration
(FDA) since 2011 were 55 [5]. According to some reports (e.g., [6]), there were at least 16 drugs for
oncology approved by the FDA in 2017. A similar high number of approvals has also been reported in
Europe, but the rather fast rate of drug approval in the recent years has not brought a real breakthrough
in cancer chemotherapy. For example, the European Medicines Agency (EMA) is reported to have
approved the use of 48 cancer drugs for 68 indications from 2009 to 2013. According to a recent
report by Davis et al. [7], however, most of these drugs did enter into the market without evidence
of benefit for patients’ survival or quality of life. In a study following 3.3 years after their market
entry, the potential of these drugs to extend or improve life for most of the indicated cancer cases was
not validated [7]. The toxic side effects of chemotherapeutic agents along with the development of
resistance coupled with metastasis, non-selectivity, bioavailability, and rapid clearance, are among the
common drawbacks of the existing available drugs.
For the above-mentioned reasons, there is still enormous appetite to discover new drugs from
natural and synthetic sources. The grim reminder is also that cancer remains the leading cause of
morbidity and mortality in the world with approximately 14 million new cases reported in 2012 [8].
Being the second leading cause of death globally, responsible for 8.8 million deaths, cancer was
also the second most leading cause of death in the world in 2015. The vast majority of mortality
(~70%) from cancer occurs in less developed countries where the cost of therapy is beyond the reach
of many patients [8]. Whether one aims to discover novel drugs or validate those natural sources
(e.g., plants) commonly used as traditional medicine in developing nations, scrutinizing decades
of research on those reported to show some promise is a vital scientific endeavor. In this regard,
the present review highlights the lessons learned from researches on the iridoid glycoside, geniposide,
and its aglycone, genipin.
2. Natural Sources of Geniposide and Genipin
The most widely reported sources of geniposide (Figure 1) are the fruits of Gardenia jasminoides Ellis
(Rubiaceae) that has been used in traditional Chinese medicine for centuries. Numerous other species
of the genus and other members of the family Rubiaceae have been known to contain geniposide.
A review article on the natural occurrence of geniposide comprising around 34 different species has
appeared recently [9]. The hydrolysis product of geniposide, genipin (Figure 1), is also found along
with geniposide and several derivatives (e.g., geniposidic acid). Other structural analogues of the
iridoid skeleton as well as compounds derived from glycosylation and further esterification with
aromatic acids have also been isolated from various plants in the last few decades [9].
The identification of geniposide as a new iridoid glycoside from G. jasminoides goes as far
back as the 1960s [10,11]. Numerous pharmacological activities of genipin and geniposide have
been reported since then, and some review articles on their antidiabetic and neuroprotective effects
(e.g., in Alzheimer’s diseases) have been published by our laboratories [12,13]. The present critical
Biomedicines 2018, 6, 39 3 of 28
review highlights progress in research with respect to the anticancer potential of geniposide and
its aglycone genipin. The two common acclaimed medicinal plant sources of these compounds in
the various literature articles reviewed herein are the fruits of G. jasminoides and Gardenia Fructus
(San-jee-chee in Chinese), which are highly cited for their medicinal uses. In these plants, geniposide is
also a major component and serves as a quality control marker of crude plant drug preparations.
For example, Yin et al. [14] have shown that geniposide accounts for 72.58–88.27% of the total
components of extracts obtained from the dried and ripe fruit of G. fructus collected from various
regions of China.
Figure 1. Structures of geniposide and its analogues. Geniposide is a natural analogue or methyl
ester of geniposidic acid. Genipin is the aglycone of geniposide which is also present in plants,
while penta-acetyl geniposide is a synthetic derivative widely employed in anticancer activity studies.
3. Physicochemical Properties and Associated Pharmacokinetics Profile
With a molecular formula of C17H24O10, geniposide (Figure 1) is a small-molecular-weight
(388.366 Da) compound. The presence of a sugar (glucose) moiety in the molecule gives the compound
its polarity with good water solubility and hence better expected bioavailability compared to its aglycone
(genipin). The partition coefficient (P) of geniposide on the basis of the octanol/water system is reported
as 0.1077, while its log p value is −0.97 [15]. This suggests that the expected rate of absorption in the
small intestine would be poor, as the compound may not be readily passing through cell membranes.
The absorption of geniposide from the crude extract of G. fructus in the rat intestine was studied by
Zhang et al. [15], and the reported absorptive rate constants (K) at the concentration of 0.078, 0.311,
0.780 g/L were 0.130, 0.056, and 0.031 h, respectively. This absorption was considered poor although
the compound was taken up in all small intestinal segments of rats, and the highest levels of absorption
were in the duodenum.
Yang et al. [16] studied the pharmacokinetics profile of geniposide after administration through
four routes in rats. The absolute bioavailability was reported as follow: F (i.g.) = 9.74%, F (intranasal,
i.n.) = 49.54%, and F (intramuscular) = 72.69%, respectively. The pharmacokinetic profiles of geniposide
following oral administrations of the pure compound and in crude herbal products were also studied
in rats and in vitro using Caco-2 cells [17]. It was reported that geniposide had a better absorption in
the duodenum and jejunum in vivo through passive diffusion. While geniposide might be the potential
substrate for P-glycoprotein as assessed by both models, an enhancement of absorption was noted
when the drug was administered in the crude (herbal) rather than in the purified form. After the oral
administration of a G. fructus extract containing 50 mg/kg of geniposide, the mean Cmax of geniposide
was 0.68 µg/mL at 0.44 h, the mean area under the plasma drug concentration-time curve (AUC) was
1.46 µg/mL/h (0.024 µg/mL/min), while the mean apparent t1/2 was estimated to be 0.94 h [18].
A study by Li et al. [19] tried to address the transformation of geniposide after absorption in
rats. The authors reported the detection of 17 metabolites in the plasma, 31 in the urine, 6 in the
heart, 12 in the liver, 3 in the spleen, 6 in the lung, 12 in the kidney, 6 in the brain, and 4 in
the liver microsomes. The transformation of geniposide included hydrolysis, hydroxylation, taurine
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conjugation, hydrogenation, decarboxylation, demethylation, sulfate conjugation, cysteine S-conjugation,
and glucosylation. Lu et al. [20–22] also conducted comparative bioavailability studies on geniposide in
mice after i.n., intragastric (i.g.), and intravenous (i.v.) administration. They reported bioavailability as
85.38% and 28.76% for i.n. and i.g., respectively, when borneol was used as a vehicle. The i.v. administration,
which does not involve any absorption mechanisms, was the best in making the drug available to tissues.
The reported AUCplasma of i.v., i.n., and i.g. were 324.88, 277.39, and 93.44 µg/mL/min, respectively [22].
All the above data suggest that geniposide has somehow a poor absorption profile but could be
readily taken up and distributed in animal tissues. The various pharmacological effects demonstrated
in animal models (reviewed in [12,13]) and discussed in the following sections also suggest that
the compound and/or its metabolites have profound effects after administration through various
routes. The pharmacokinetic profile of its aglycone, genipin, is however not readily available for
comparison, although few pioneering studies of significance are worth mentioning. A study by
Ako and Kobashi [23,24] have shown that geniposide, once orally administered, is converted to
genipin in the intestine, which acts as the active principle. β-D-glucosidases activities of the intestinal
bacteria were implicated in this transformation. A study by Yim et al. [25] further established that
the transformation of glycosides into a bioactive aglycone form is extended to other natural products,
such as ginsenoside Rb1, glycyrrhizin, and baicalin. In our recent review article on rutin and its
aglycone, quercetin, as potential therapy for inflammatory bowel diseases, the transformation of
a glycoside form to a bioactive aglycone molecule in the intestine was highlighted [26]. When quercitrin
was anaerobically incubated with human intestinal bacteria, the main product was also found
to be quercetin [27]. Moreover, a range of reactions, including hydroxylation, demethylation,
deglycosylation, and ring-cleavage can occur under the action of intestinal bacteria, and compounds
like quecetrin can give rise to bioactive molecules such as 3,4-dihydroxybenzoic acid [28]. Hence,
intestinal transformation and absorption (Figure 2) must be considered from the outset when one
is assessing the anticancer potential of geniposide and its aglycone. In this regard, a study by
Kang et al. [29] is a further example elaborating this therapeutic principle. They have reported
that the aglycone genipin is much more cytotoxic to human hepatoma HepG2 cells than geniposide.
Moreover, the metabolic activation system for geniposide was confirmed to be the passage through the
intestine, as human intestinal bacterial cultures (Bifidobacterium longum HY8001 or Bacteroides fragilis)
or fecal preparations could activate geniposide to kill cancer cells. The absorption of geniposide into
the blood stream in its intact form could also be augmented if antibiotics were used to suppress the
activity of intestinal bacteria [30].
Figure 2. Transport mechanisms of geniposide and genipin. The absorption of geniposide, which is
predominantly present in plant extracts, could be enhanced by transformation in the gut through the
action of bacterial β-glucosidase enzymes. Other preparations, such as borneaol or crude plant extracts,
could increase the absorption from the gut. The bioactive molecule, genipin, is highly non-polar and
water insoluble, and a formulation strategy is required to maximize its absorption.
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The hydrolysis of geniposide to genipin by β-glucosidase could also be studied directly by
using purified enzymes. Hence, the immobilized glycosyl hydrolase family 3 β-glucosidase has been
effectively used to convert geniposide in a hot-water extract of G. fructus into genipin [31]. With respect
to probiotic applications, the role of lactic acid bacteria (Lactobacillus sp.) in the intestine in food
transformation and hydrolysis of glycosides (e.g., ginsenoside Rd and glucosidic isoflavones) using
β-glucosidase are well understood [32,33]. Furthermore, Lactobacillus rhamnosus GG strain (LGG) has
been shown to enhance the in vitro anticancer effects of geniposide [34].
The above data have profound implications on the extraction of bioactive compounds from natural
sources, drug formulation, and pharmacokinetic and/or pharmacodynamics parameters. For example,
a drug molecule of nonpolar nature that is of interest in vitro could be rather administered in its
glycosidic form not only to increase its bioavailability but also to convert it to its more bioactive form
in the intestine. The extraction of compounds by non-polar solvents that may give a good bioactivity
in vitro may also lead to non-bioactive molecules in vivo, given the biotransformation issue discussed
above. As shown in the following sections, the relative potency of genipin and geniposide varies:
while genipin is profoundly more active in vitro, its concentration in many plants (for example in
G. fructus) is far lower than that of geniposide. Hence, the anticancer effect of such plant extracts is
partly a result of the biotransformation of the orally administered preparations in the gut, and, hence,
future anticancer drug development prospects should consider enzyme-catalyzed tools in converting
glycosides into bioactive aglycones (Figure 2).
4. Anticancer Effects of Geniposide and Genipin
4.1. Direct Cytotoxic Effect on Cancer Cells
The assessment of direct cytotoxicity on cancer cells, often in combination with the measurement of
apoptosis events, are common in vitro assays employed to show potential anticancer effects of natural
products. Genipin and geniposide have been shown to be cytotoxic in numerous cancer cell types
including colorectal cancer [35,36], pancreatic adenocarcinoma cells [37], AGS and SNU638 human
gastric carcinoma cells [38–40], non-small-cell lung cancer H1299 cells [41], prostate (DU145 and PC3)
cancer cells [42–44], hepatocarcinoma (HepG2 and Hep3B) cells [45,46] breast cancer (MDA-MB-231)
cells [47], human leukaemia (K562, HL-60, U266, U937) cells [48–50], and tongue squamous carcinoma
(HSC-3) cells. The acetylated product of geniposide, penta-acetyl geniposide (Figure 1), has also been
investigated and has shown in vitro cytotoxicity in a range of cell lines, such as C6 glioma cells [51–57].
While the in vivo effect of compounds following oral administration could be variable, depending
on intestinal transformation, direct cytotoxicity or induction of apoptosis are often more pronounced
for aglycones than for their glycosidic analogs. For example, the flavonoids quercetin and myricitin are
more potent in the induction of apoptosis in cancer cells than their corresponding glycosides quercitrin
and myricitrin, respectively [58,59]. Despite some unique and general mechanisms (see following
sections) attributed to the anticancer effects of geniposide and genipin in various cancer cells lines,
we should be cautious about their value as anticancer lead compounds. The effective dose of geniposide
is far higher than 100 µM and hence should be considered weak. Even for its acetate derivative, which is
considered more active, many studies used 200 or 300 µM as effective doses (e.g., [55,60], while some
studies even used 600 µM (e.g., [53]). On the other hand, for the anticancer compound genipin
(more active in vitro than geniposide), which displays cancer growth inhibition at a lower micromolar
range concentrations, the most effective doses shown in various studies remain around 100 and
200 µM [35,37,42,45,48,61]. In this regard, the IC50 of genipin in H1299 cells was 351.5 µM [41]. In the
search of novel potential anticancer agents from natural and other sources, activities (IC50 values) in
nanomolar ranges are often considered potent, while those in the submicromolar or micromolar ranges
are considered promising. The various plant-derived cytotoxic agents of clinical significance fall within
this last category. For example, the IC50 value of paclitaxel in various human tumour cell lines range
between 2.5 and 7.5 nM) [62]. In our laboratories, many terpenoids that merited a report as potential
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anticancer agent have an IC50 lower than 20 µM and are considered very active when an activity far
lower than 10 µM is achieved [63–66]. An activity up to 50–100 µM may be considered moderate in
view of potent compounds, such as the podophyllotoxin analogues, that we have isolated from natural
sources with a potency in the nanomolar range and that comparable to taxane [67]. Considering
these scenarios, the reported anticancer effect of geniposide is nothing but weak. The mismatch
between the high number of publications on natural products with potential anticancer effect and
the number of those products making it into the development stage is thus partly due to the poor
intrinsic potency these compounds are endowed with. For example, many terpenoid compounds
that we showed to have general cytotoxicity in cancer cells possess one or few α,β-unsaturated
carbonyl groups that could initiate a Michael-type addition reaction leading to cell damage and/or
cytotoxicity. To date, manyα,β-unsaturated carbonyl compounds are known to display tumour-specific
cytotoxicity through Michael acceptor mechanisms, and their activity could also be reversed by
N-acetylcysteine [68]. Geniposide and genipin possess this structural moiety (Figure 1), and, even
though multiple mechanisms (see next section) are implicated, such general mechanism could be
implicated in their rather weak action as cytotoxic agents in cancer cells. In fact, their cytotoxicity and
other biological effects that are mediated via the generation of reactive oxygen species (ROS) have been
shown to be reversed by an antioxidant such as N-acetylcysteine [69]. Moreover, compounds containing
such structural moiety are also known to display antibacterial effects against the common gram-positive
bacteria [70–72], an effect that is shared by genipin/geniposide [73]. Keeping in mind that the general
mechanism of the above-mentioned structural moiety is evident in biological systems [74], the in vivo
anticancer effect of these compounds is also demonstrated. For example, when C6 glioma cells were
inoculated into rats, some tumour growth inhibition was observed after treatment with penta-acetyl
geniposide at doses of 5 and 10 mg/kg [56]. The most pronounced effect was, however, observed
when the drug was administered as a pre-treatment, for which the latency period T50 (time for 50%
tumour incidence) was prolonged. The reported growth inhibition at week 7 of treatment with the two
doses was 41% and 75%, respectively [56].
4.2. Effects on Carcinogenesis
As discussed above, doses as small as 5 and 10 mg/kg of penta-acetyl geniposide have been
demonstrated to increase the latency of tumour development in animals. Lee et al. [75] investigated
the potential effect of the topical application of geniposide on 12-O-tetradecanoylphorbol-13-acetate
(TPA)-induced promotion of skin tumours in mice previously initiated with benzo[a]pyrene. In this
model, geniposide (0.2 or 1.0 µMol) administered with TPA (15 nmol) twice weekly for 20 weeks was
reported to suppress tumour growth by 84% or 89%, respectively. In the same model, geniposide
also inhibited the induction of epidermal ornithine decarboxylase activity by TPA (5 nM), as well
as skin inflammation (TPA-induced oedema of mouse ears by 41% or 43%, respectively). Other
markers of inflammation induced by TPA in the mouth skin, such as hydrogen peroxide (H2O2)
and myeloperoxidase, were also suppressed. In another study by Wang et al. [76], the inhibitory
effect of geniposide on aflatoxin B1 (AFB1)-induced DNA repair synthesis in primary cultured rat
hepatocytes were investigated. The authors showed that geniposide could suppress the AFB1-induced
DNA repair synthesis through an increased AFB1 detoxification metabolism. Hence, the activities
of glutathione (GSH)-S-transferase (GST) and GSH-peroxidase (GPx) in AFB1-treated cultured cells
were shown to be enhanced by geniposide. Other studies on cultured AFB1-treated C3H10T12 cells
showed that penta-acetylated geniposide could interfere with the aflatoxin-induced DNA damage
and repair processes [77]. In line with these in vitro effects, Wang et al. [78] also demonstrated that
geniposide could suppress hepatic AFB1–DNA binding and AFB1 hepatotoxicity in rats. Serum marker
enzymes of the liver, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT),
and γ-glutamyltranspeptidase (γ-GT) were elevated following treatment with geniposide (10 mg/kg)
daily for three consecutive days. These data, along with the amelioration of the AFB1–DNA adduct
formation by geniposide [78], is in line with the suggested chemopreventive properties and/or
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anticarcinogenic potential of geniposide. Lin et al. [79] also assessed the potential of this compound in
suppressing the development of γ-glutamyl transpeptidase (GGT)-positive foci induced by AFB1 in
rats. The rational of the experimental model appears to be related to GGT inhibition being a target
of AFB1-induced hepatocarcinogenesis. Since pioneering studies proposing a crucial role for GGT in
cancer development in the 1980s, it potential as a target in various stages of cancer progression has
been established. Hence, some competitive and non-competitive inhibitors, including the glutamate
analogs, have been shown to be promising as potential anticancer agents [80–82]. Upon exposure
to AFB1 (like in cases of diet contaminated with aflatoxins), an increase in the GGT-positive foci
have been widely reported, while the activity of the enzyme in hepatocytes in normal individuals
is maintained at a very low level. Data by Lin et al. [79] revealed a suppressive effect of geniposide
on the AFB1-induced GGT-positive foci (with a diameter larger than 0.3 mm). More importantly,
the doses employed (1 and 2 mg/kg, p.o.) to achieve this outcome were very low. This effect is related
to the pro-oxidant/antioxidant effect of geniposide discussed in the following sections. Located on the
cell surface, GGT hydrolyzes the extracellular GSH and increases the intracellular amino acid pool
for GSH synthesis. The high level of ROS in cancer cells could thus be mitigated through the action
of GGT, a mechanism which is crucial for carcinogenesis and drug resistance to chemotherapeutic
agents. Excellent review articles on GGT physiology and pharmacology are available [83,84]. As with
geniposide, many natural products, such as green tea epicatechins, have been shown to act through
GGT inhibition to induce their antimutagenic and anticarcinogenic effects [85]. The anticarcinogenic
mechanism of genipin/geniposide could also be attributed to the general antioxidant mechanism that
is common to many natural products. The induction of nuclear factor-erythroid-2-related factor 2 (Nrf2)
antioxidant enzyme along with GPx by genipin has been shown in AGS cell line [39]. This antioxidant
effect was, however, shown at smaller doses (less than 25 µM) of genipin treatment, which were also
associated with C-Jun-NH2-kinase (JNK) activation by the compound. Hence, readers should note
that such an action may not be evident at the high doses of genipin mediating anticancer effects.
Another mechanism by which these compounds may exert anticancer activity could be associated
with their antiviral effects. A study by Son et al. [86] demonstrated that genipin (70 µM) can have
antiviral effects against Epstein–Barr virus (EBV). As EBV causes several human cancers [87,88],
an antiviral effect could have implications in the protection against virus-induced carcinogenesis.
A study by Cho et al. [89] also showed an effect of genipin against the Kaposi’s sarcoma-associated
herpesvirus (KSHV). The IC50 for genipin was, however, reported as 49.5 µM in iSLK-puro
(KSHV-negative) cells and 72.5 µM in iSLK-BAC16 (KSHV-positive) cells. Hence, its effect in this viral
system is not in favour of antiviral effect, but to the contrary, it could promote KSHV latent replication
at lower concentrations [89]. By using the murine model of influenza respiratory tract infection,
Zhang et al. [90] demonstrated the antiviral effect of geniposide against pandemic A/Jiangsu/1/2009
(H1N1) influenza virus. The antiviral effect of geniposide against EV71 virus has also been reported [91].
Hence, even though further research is required, some of the reported antiviral effects could be
implicated in the anticarcinogenic activity of genipin and geniposide analogs.
4.3. Effects on Cancer Metastasis
Wang et al. [46] studied the anti-metastatic potential of genipin in human hepatocellular
carcinoma cells in vitro. They showed, through an orthotopical implantation model, that genipin
could suppress the formation of intrahepatic metastases as well as tumour expansion in the liver at
its non-toxic concentrations (60–120 µg/mL). Cell motility and invasiveness through extracellular
matrix (ECM) were also inhibited by genipin. The authors also presented an interesting insight
into the mechanism of action of genipin. While the expression levels of matrix metalloproteinase-2
(MMP-2) (mRNA or protein) were not affected, genipin was shown to upregulate the expression
of the endogenous inhibitor of MMP-2, i.e., tissue inhibitor of matrix metalloproteinase-1 (TIMP-1).
This effect of genipin was also correlated with the activation of p38 mitogen-activated protein kinase
(MAPK) signaling, which appeared to be correlated to apoptosis induction by genepin in cancer
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cells (see below for mechanisms of action). A study by Huang et al. [92] on the penta-acetylated
geniposide also showed anti-metastatic potential of this compound in rat neuroblastoma (C6 glioma)
cells, wherein inhibitory effects were observed in cell-matrix adhesion, wound healing, and Boyden
chamber assays. In agreement with the report by Wang et al. [46], these researchers also observed
a decreased activity of MMP-2 in a gelatin zymography assay and increased levels (mRNA) of
TIMP-2; however, in contradiction with this, reduced mRNA levels of MMP-2 and of membrane
type I matrix metalloproteinase (MT1-MMP) were reported [92]. Another inhibitory effect of
penta-acetylated geniposide was observed on the protein expression of phosphoinositide 3-kinase
(PI3K), the phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), and the
activation of transcription factor nuclear factor κB (NF-κB), c-Fos, and c-Jun. Readers should note that
the in vitro cell migration assays were conducted at concentrations of 0.15 or 0.3 mM, and the best
effective dose of 0.3 mM employed (non-toxic concentration) should be considered rather high. Other
studies have shown that genipin could suppress the invasive/migratory abilities of the highly invasive
MDA-MB-231 human breast cancer cells, suggesting a potential effect in breast cancer metastasis [47].
The inhibitory effect of genipin on vascular smooth muscle cell proliferation and migration
through tumour necrosis factor-α (TNF-α) suppression has been studied by Jiang et al. (2013) [93].
They have shown that this effect was mediated through the induction of haem oxygenase-1 (HO-1),
the expression/activation of ERK/MAPK, and the phosphorylation of protein kinase B (PKB or Akt),
without a significant effect on p38 MAPK and JNK. In their assay, the generation of ROS by TNF-α
was also blocked. The study by Kitano et al. [94] on the anti-fibrogenic effect via decreasing TGF-β1
expression in human sub-conjunctional fibroblasts has also implications on wound healing and cancer
metastasis. They showed that genipin could suppress wound-induced cell migration and proliferation
of fibroblasts by decreasing collagen type I (mRNA and protein), transforming growth factor β1
(TGFβ1), and α-smooth muscle actin (αSMA) expression. Smad2 (mothers against decapentaplegic
homolog 2; also known as SMAD family member 2) signaling was also inhibited by genipin [94].
On the basis of the above reported findings, multiple mechanisms appear to be involved in the
potential cancer growth and metastasis inhibitory effects of genipin. First, the solid tumour mass
must disintegrate to release cancer cells that would travel and invade new tissues to establish foci
of cancer cells. This requires the degradation of adhesion molecules (e.g., cadherins) that keep cells
together in tissues (reviewed in [95]). ECM degradation by a range of proteolytic enzymes, including
matrix metalloproteinases (MMPs), is another important feature of cancer metastasis [96–98]. During
metastasis and its related pathological process, angiogenesis, ECM degradation results in the activation
and/or release of various mediators that increase cell proliferation, invasion, and angiogenesis.
The migration of cancer cells through ECM, blood media, and tissues mirrors that of leucocyte
infiltration into extravascular tissues under inflammatory conditions. Hence, several key molecular
and biochemical targets are shared by these two processes. The modulation of cell-cell and cell-matrix
interactions is thus fundamental for a cancer cell to migrate, invade, or escape from destruction by
the immune system. The MMPs, through their zinc endopeptidases action, degrade a plethora
of proteins ranging from proteinases, MMPs themselves, proteinase inhibitors, growth factors,
chemokines, cytokines, and various cell adhesion molecules. Hence, the potential of genipin to
modulate cancer metastasis through effects on MMPs appears to be established. Another feature of
metastasis overlapping with inflammation is the signal transduction pathway mediated by NF-κB.
Many natural products have been shown to modulate cancer metastasis through an effect on the NF-κB
mobilization [99]. As demonstrated for genipin above, a number of studies have also shown that
the activation of MMPs (MMP-1, -2, -3, and -9) is regulated by the PI3K, NF-κB, and AP-1. As with
inflammation and angiogenesis, cancer metastasis has also been shown to involve MAPK (e.g., JNK,
p38, and ERK), which appear to be regulated by genipin. More data on angiogenesis including the
effect on key mediators, such as the vascular endothelial growth factor (VEGF), and in vivo evidence
are needed to further validate the potential of these compounds as anti-metastatic agents.
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Undoubtedly, multiple mechanisms of action take part in the anti-metastatic effect of
geniposide/genipin and of the crude extract preparations of plants that produce them. Following
the demonstration of the potent anti-angiogenic activity of G. jasminoides Ellis in the chick embryo
chorioallantoic membrane assay, a bioassay-guided isolation study identified geniposide as the
active principle [99]. In a further experiment by Koo et al. [100], genipin was also shown to
have an antiangiogenic effect, when assessed in the chick embryo chorioallantoic membrane assay.
Moreover, data from lipopolysaccharide/interferon-γ (LPS/IFN-γ) in RAW 264.7 cells showing
inhibition of NF-κB activation, nitric oxide (NO) production, and inducible nitric oxide synthase
(iNOS) expression (50–300 µM) show the existence of an anti-inflammatory–antiangiogenic crosstalk.
Hence, anticarcinogenesis, antiangiogenic effects, and direct effects on established cancer cells are all
involved in the mechanism of action for these compounds. The overall gross mechanism of action of
these compounds is depicted in Figure 3.
Figure 3. The various stages of cancer development and their potential modulation by genipin
and analogs. Genipin/geniposide appear to target almost all stages of cancer development via
multiple mechanisms.
5. Lessons on the Mechanisms of Action
5.1. Mechanisms Related to Cell Cycle Regulation
Induction of apoptosis by anticancer agents is one of the common and rather gross mechanisms
leading to cellular morphology and biochemical alterations and death. The induction of apoptosis and
the inhibition of cellular proliferation by geniposide and genipin have been shown to be coupled with
cell cycle arrest [38]. For example, G2/M phase arrest along with the induction of cyclin-dependent
kinase inhibitor p21 (p21) and p21-dependent cyclins were shown to be induced by genipin in AGS
human gastric cancer cells. As one expects, signalling pathways associated with this process are
inevitably affected by genipin, and the transcription factor early growth response-1 (Egr1)-p21 crosstalk
(both elevated by genipin at protein and mRNA levels) is among the mechanisms already reported.
Egr1, as a transcription factor, could upregulate p21 by binding to the p21 promoter, following
its translocation in the nucleus. Data by Ko et al. [38] thus gave some clue on the mechanism of
apoptosis induction by genipin via caspase 3 and a p53-independent mechanism in the Egr1–p21
signaling pathway. They also showed that genipin increased p21 promoter activity and the interaction
between Egr1 and the p21 promoter site in a dose-dependent manner. By inhibiting the activity of
cyclin-dependent kinases, which are required for cell cycle progression, p21 induces cell cycle arrest
at either the G1/S phase or the G2/M phase. The other most important mechanism observed in the
study was the generation of ROS and the increase in mitochondrial permeability following genipin
treatment. Mitochondrial permeability could predispose cells to necrotic and apoptotic cell death
(see the following sections). Depending on the cell type and concentrations used, some differences in
the cancer cell killing mechanisms may be evident. For example, Chang et al. [51] demonstrated an
increase in p53, c-Myc, and B cell lymphoma gene 2 (BCL2) associated X (Bax) coupled with a decreased
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protein levels of B cell lymphoma gene 2 (Bcl-2) associated with the cytotoxic effect of penta-acetylated
geniposide in C6 glioma cells. The cell cycle arrest reported was at G0/G1 at 0.3 mM, a dose slightly
higher than the IC50 value (0.2 mM-52% cell viability inhibition).
A mechanism involving increased phosphorylation of p38 MAPK in genipin-induced apoptosis
was demonstrated in non-small-cell lung cancer H1299 cells, via a mitochondrial apoptotic cascade [41].
Hence, increased levels of Bax and suppression of Bcl-2, coupled with the activation of the
mitochondrial execution pathway through caspase-9 and -3 activations were reported after genipin
treatment. The cell cycle arrest at the G2/M phase reported by these authors was also in line with
what has already been discussed above, reported in other studies [38]. The downregulation of
Bcl-2, the upregulation of Bax, and the proteolytic activation of caspase-3, along with the activation
of JNK and p38 MAPK, were also established in MDA-MB-231 human breast cancer cells [47].
In human leukaemia K562 cells, the induction of apoptosis by genipin (200–500 µM) was coupled
with upregulated Fas-L expression, increased caspase 3 activity, cell cycle arrest at the G2/M phase,
and upregulated p-JNK, p-c-Jun, Fas-L, Bax, and cytochrome C [48].
Hwang et al. [43] studied the mechanism of action of genipin after hydrolysis of geniposide,
as the latter appeared a very weak anticancer agent in vitro (see Section 4.1 above). In cancer cells
such as DU145, MDA-MB-231, and U266, they showed that genipin could inhibit the constitutive
signal-transducer-and-activator-of-transcription-3 (STAT3) activation by suppressing upstream Janus
kinase 1 (JAK1) and c-Src. The expressions of Bcl-2, Bcl-xL, survivin, and cyclin D1 were downregulated,
leading to cell cycle arrest at sub-G1 phase and apoptotic cell death. Cell cycle arrest at the G1
phase (along with increased levels of phosphorylated JNK, phospho-Jun, p53, and Bax proteins)
was also observed in HeLa cells subjected to apoptosis by genipin [42]. In this regard, the effect of
geniposide was consistent with that reported in various other studies, where anti-apoptotic gene
products were suppressed. Given that STAT3, following activation, dimerizes and translocates into
the nucleus to regulate the expression of various genes involved in cell survival, such as Bcl-2, Bcl-xL,
and survivin, its inhibition could be a mechanism of apoptosis induction. For detailed insights into the
subject, readers are directed to review articles [101,102] that outline constitutive STAT3 activation as
a common biochemical marker of various cancer types and its targeting by potential chemotherapeutic
agents. The cleavage of procaspase-8 and procaspase-9 could also be shown to be induced by genipin
following inhibition of STAT3 activation, while caspase-3 was also activated [43]. JAK1 and c-Src
are upstream protein tyrosine kinases that appeared to be inhibited by genipin along with STAT3
phosphorylation. Experiments by Lee et al. [49] also corroborated the above findings: In U266 and
U937 cells, the suppressive effect of genipin on the constitutive STAT3 activation was shown to be
mediated by the suppression of the activation of c-Src, but not JAK1. Furthermore, c-Src homology
2 domain-containing phosphatase-1 (SHP-1), which dephosphorylates and inactivates STAT3, was
activated by genipin. In line with other studies (e.g., [43]), STAT3 target genes, such as Bcl-2, Bcl-x(L),
survivin, cyclin D1, and VEGF, were downregulated.
Hong and Kim [44] examined the role of the mixed lineage kinase 3 (MLK3) in the ROS-
and JNK-induced mitochondrial apoptosis in genipin-treated PC3 human prostate cancer cells.
In these cells, sub-G1 cell cycle arrest, apoptotic cell death through activation of caspase, collapse of
mitochondrial membrane potential, and release of cytochrome C were common features following
genipin treatment. Genipin also stimulated MLK3 in these cells and generated ROS, processes that
were both dependent on NADPH oxidase. As the phosphorylation of JNK and the induction of JNK by
genipin were markedly inhibited in PC3-EGFP-MLK3 (K144R) cells expressing a dominant-negative
MLK3 mutant, ROS- and MLK3-dependent apoptosis in these cells was suggested to be mediated
through downstream activation of JNK. Another observation in this study relates to the fact that
a specific inhibitor of p38 (PD169316) failed to suppress genipin-induced apoptotic cell death, hence
highlighting the various possible pathways of apoptosis induction by this compound in different cell
systems or at variable doses. On the other hand, penta-acetylated geniposide-induced cell death in
C6 glioma cells was shown to be dependent on MAPK, including p38 (and also ERK and JNK) [52].
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Sphingomyelinase (SMase)/nerve growth factor (NGF)/p75 activity in these cells, along with increased
activity of the activator protein-1 (AP-1) and NF-κB and expression of FasL and caspase 3, have been
shown to participate in cell death [52]. The NGF/p75 pathway appeared to be downstream of
N-SMase/ceramide, while both were upstream of protein kinase Cδ (PKCδ) [53]. One must note
that the experiments in this case were conducted at 0.6 mM penta-acetyl geniposide, a concentration
far higher than that used in other studies, although lower concentrations (0.3 mM) have also been
shown to induce the expression of PKCδ [55]. The study by Chang et al. [51] on C6 glioma cells
apoptosis and cells cycle arrest at the G0/G1 (G1–S transition) phase by this compound (0.3 mM)
similarly revealed p53 and c-Myc induction that also involved Bcl-2 family proteins, a decrease in the
protein expression of cyclin D1, increased levels of cyclin-dependent kinase (cdk) inhibitor p21 protein,
suppressed formation of cyclin D1/cdk 4 complex, inhibition of the phosphorylation of retinoblastoma
(Rb), and dissociation of the Rb/E2F complex.
Overall, the induction of apoptosis by genipin and geniposide involved the activation of caspases
that are known to mediate the common morphological changes, including DNA fragmentation,
membrane blebbing, and the formation of apoptotic bodies, that were widely reported along with cell
death. One common mechanism of action for these compounds appeared to be related to modulation
of gene expression. Bcl-2 is a cell survival oncogene that prevents apoptosis, hence promoting cancer
malignancies [103,104]. One of the various functions of the Bcl-2 family of proteins is the inhibition of
cytochrome C release from mitochondria that triggers the apoptosis cascade. Hence, suppressing the
expression of Bcl-2 predisposes cancer cells to increased apoptosis and cell death, as evidenced for
various anticancer drugs. Other genes and proteins related to Bcl-2 are BCL2 antagonist/Killer 1 (BAK)
and Bax, which are pro-apoptotic and hence have the opposite function of Bcl-2, i.e., they induce the
release of cytochrome C and other proteins and trigger apoptosis through caspase activation [105].
On the other hand, p53 is a tumor suppressor gene/protein that is also involved in the regulation of
cell growth/death. As a transcription factor, p53 binds to DNA to control cellular activities, including
the induction of DNA damage and cell cycle regulation leading to apoptosis. For this, p53 acts as
transcription factor for genes coding for pro-apoptotic effector proteins and also orchestrate death
signaling through the mitochondria and cytoplasmic cascades [106–108]. The transcription of enzymes
involved in the repair of DNA is also induced by p53 [109]. In the various studies mentioned above for
geniposide and analogues, modulation of the various cell survival/death regulatory genes/proteins
has been demonstrated. The effect of genipin on signal transduction pathways, including those
regulated by kinases, is similar to that of many clinically useful drugs. By inhibiting tyrosine kinases
such as mitogen-activated protein kinase kinase (MEK1/2)-ERK1/2 signaling, the therapeutic potential
of imatinib, gefitinib, and sunitinib has been validated [110].
The role of cell cycle regulation in the treatment of various cancers has been extensively reviewed
(e.g., [111–113]). The cell division cycle is divided into distinct phases and include the Gap 0 (G0—resting
stage), G1 (gap phase 1), synthesis (S) (DNA synthesis), G2 (gap phase 2), and M (mitosis) phases.
Besides the role of various genes and protein kinases, the regulation of the cell cycle is under
direct control of the various cyclins and cyclin-dependent kinases (cdks—which are serine/threonine
kinases). D-type cyclins have been widely known for regulating cell cycle progression and tumorigenic
cascades [114]. The interaction between cyclins and cdks is important in the smooth transition between
the various stages of the cell cycle. Inhibitors, including those acting on p21 and various other associated
proteins such as the nuclear transcriptional factors E2F-1 and Ets-1, also play important roles in cell cycle
regulation. Various external stimuli that damage DNA, such as ionizing and UV radiations as well as
many chemotherapeutic drugs, can induce inhibitors such as E2F1 [115]. The binding and/or activation
of Cdk4 and Cdk6 with Cyclin D1 promotes G1/S-phase transition. Hence, the overexpression of cyclin
D1 could promote tumorigenesis. The activation of p53 also leads to transcriptional downregulation of
cell cycle proteins [116]. Another tumor suppressor protein in cancer cells is Rb which is inactivated
through phosphorylation by the various cyclin cdks, leading to progression of the cell cycle through
G1 into S. Hence, the effects of genipin and geniposide in the various studies discussed above as
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modulators of cell cycle arrest through pathways involving cyclins, cdks, and associated genes and
signaling pathways outlined their possible mechanisms of action.
In view that the cytotoxic effects of genipin/geniposide occur at fairly large concentrations,
multiple mechanisms may be involved. Gálvez et al. [117], for example, showed topoisomerase
I poisoning by geniposide as another possible mechanism of action. Along with another iridoid
glycoside, aucubin, the compound could stabilize the covalent attachment of topoisomerase I (but not
topoisomerase II) subunits to DNA at sites of DNA strand breaks.
5.2. General Anti-Inflammatory Mechanisms
Carcinogenesis and inflammation have many overlapping signaling cascades in common. Key
inflammatory mediators, such as (interleukin 1 (IL-1), IL-6, and TNF-α) are also implicated in
carcinogenesis as well as in established cancer biology processes [118]. The expression of these
cytokines is mediated through the activation of some common transcription factors, such as NF-κB,
AP-1, STAT3, and Smad. Hence, while agents that chronically induce the expression of transcription
factors such NF-κB and STAT3 could induce carcinogenesis [119,120], the same mechanism could be
targeted by therapeutic agents to inhibit tumorigenesis. While chronic inflammation can increase the
oncogenic potential of normal cells by its own, viral-induced carcinogenesis could also be mediated
through enhanced oxidative stress and inflammatory mechanisms [121]. Besides cytokines, various
chemokines and prostaglandins that are implicated in inflammation through their autocrine and
paracrine effects are also known to participate in cancer biology [122]. Moreover, other carcinogenic
agents such as UV irradiation do also trigger the inflammatory process in the body, including the
induction of prostaglandins and cytokines that mediate carcinogenesis [123,124]. The link between
cancer metastasis and inflammation is even clearer, as the process of angiogenesis and wound healing
biology share many common features, and cancer metastasis also exploits the various biochemical
and molecular sequels of leucocyte infiltration into extravascular tissues. For details of the crosstalk
between cancer and inflammation, readers are directed to review articles on this subject [125–128].
On the basis of the above-mentioned cancer-inflammation crosstalk, the anti-inflammatory effects
of genipin and geniposide are worth mentioning. Genipin has been shown to suppress the production
of TNF-α both in vivo and in vitro [129]. In a cultured mouse macrophage-like (J774.1) cell line,
50 µg/mL (but not 10 µg/mL) could suppress TNF-α production, while mice pre-treated with genipin
(100 mg/kg, i.p.) could be protected (53%) from the lethal dose of galactosamine/LPS. The antioxidant
effect of genipin and geniposide that correlates with their antidiabetic effect has been well demonstrated
(reviewed in [13]) and includes the induction of antioxidant HO-1 and GSH via induction of Nrf2 [130].
Through induction of HO-1, genipin can also inhibit TNF-α-induced vascular smooth muscle cell
proliferation and migration [93]. The anti-inflammatory mechanisms of these compounds in the
Alzheimer’s brain (e.g., [131,132] have been extensively reviewed recently [12]. The effect of genipin
in gastrointestinal tract inflammation, including that induced by HCl-ethanol in an acute gastritis
model, has also been established [40,133]. In the dextran sulphate sodium-induced colitis in mice,
genipin was shown to display anti-inflammatory and protective effects against mucosal damage [134].
The suppressive effects on proinflammatory cytokines and NF-κB activation have were shown in both
animal models and in vitro in LPS-activated Caco-2 cells [134].
The anti-inflammatory effects of genipin and geniposide have also been demonstrated through
various other experimental models. By suppressing ERK1/2 signalling pathway, geniposide could
suppress the inflammatory response in brain microvascular endothelial cells (Li et al., 2016) [135].
In LPF/IFN-γ stimulated murine macrophage (RAW 264.7) cells, genipin (50–300 µM) inhibited NO
production and iNOS expression via NF-κB inhibition [136]. In vivo, both genipin and geniposide
showed anti-inflammatory effects in carrageenan-induced rat paw oedema, carrageenan-induced air
pouch formation, and affected NO content in the exudates [137]. These effects were demonstrated at doses
from 50 to 400 mg/kg, with genipin being more potent than geniposide. Genipin (0.55–4.42 µMol/year)
was also shown to have topical anti-inflammatory effects, as inhibition of the croton oil-induced ear
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oedema in mice was observed [136]. The antithrombotic activity of genipin and geniposide have also
been widely reported (e.g., [138,139]). Both act through antioxidant and anti-inflammatory effects,
exerting organoprotective effects in the neuronal and hepatic systems [140–147]. Hence, the known
anti-inflammatory effects of these compounds could play part in abolishing the critical inflammatory
component of cancer at various developmental stages (carcinogenesis, maintenance, and metastasis).
5.3. Cancer Cell Killing by Weaponizing Oxygen
Reactive oxygen species (ROS) include radical species such as superoxide anion radical (O2) and
hydroxyl radical (OH·), and non-radicals such as H2O2. They are produced under normal physiological
conditions through a variety of mechanisms, such the induction by cytokines, and under stress or
inflammatory conditions. ROS are involved in the regulation of signal transduction in various cellular
processes, including promotion of cell proliferation at submicromolar or micromolar concentrations.
Higher levels (e.g., over 100 µM) of ROS are, however, known to induce apoptosis, while even greater
concentrations, in the mM range, could induce rapid (necrotic) cell death within minutes because
of cell membrane destruction. Numerous studies in the last few decades outlined that cancer cells
development is dependent on low but chronic levels of ROS generation [148–150]. Hence, drugs that
induce the generation of ROS intracellularly could have potential anticancer effects. In this connection,
many existing anticancer drugs, such as the anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin,
and idarubicin), appear to work through such mechanisms [151]. Intriguingly, many compounds
that are regarded as antioxidants, including a range of phytochemicals, are also known to induce
the generation of ROS at low concentrations. Examples of antioxidant polyphenols inducing the
generation of ROS include flavonoids [152,153], eugenol [154], quercetin [155], resveratrol [156],
nordihydroguaiaretic [157], and curcumin [158]. We have also identified many other compounds that
can induce pro-oxidative biological effects in the presence of copper ions, as well as cytotoxicity
in cancer cells [159–164]. While the antioxidant effects of such compounds might explain their
anticarcinogenic effects, their cytotoxicity and/or apoptosis induction is associated with ROS
generation mechanisms. Even within the antioxidant polyphenols, however, some compounds and
structural groups display more pro-oxidative effects than antioxidant effects and may also potentiate
the cytotoxicity of other drugs (e.g., TNF-α) in cancer cells [163]. Interestingly, even known antioxidants
such as vitamin E and ascorbic acids do also possess pro-oxidant effects [164–166] and mediate
apoptosis through ROS mechanisms.
The generation of O2− from molecular oxygen constitutes the initial step of ROS production in
the mitochondria [167,168]. In immune cells, such as white blood cells, ROS generation primarily
through NADPH oxidase is also a fundamental process in the body’s defence against pathogenic
microorganisms and malignancy. The mitochondria are a source not only of ROS implicated in
carcinogenesis and cancer cell killing by drugs but also of a range of proteins involved in cell cycle
survival/death regulations. Hence, mitochondrial membrane damage and membrane potential
are among the common parameters measured in apoptosis assays. A compromised mitochondrial
membrane leads to leakage of proteins into the cytosol, including cytochrome C, to induce caspase
activation. As outlined in the previous section, induction of apoptosis by genipin and geniposide
through mitochondria-dependent or independent pathways has been shown to be associated with
the generation of ROS in various cancer cell lines. One of the link between ROS and induction of
apoptosis is the stress-activated protein kinase (SAPK) or JNK. When ROS are activated by drugs or
any other stimuli (UV irradiation, heat shock, GSH depletion, and many chemotherapeutic drugs),
the activation of JNK is initiated leading to induction of apoptosis. In the experiment by Kim et al. [45],
genipin-induced apoptosis in hepatocarcinoma cells (Hep3B cells) was shown to be mediated by
ROS/JNK activation of the mitochondrial pathway. JNK1/2 but not MEK1/2 nor p38 MAPK was
shown to be activated. Transfection (of c-Jun) and inhibition studies (with NADPH oxidase) further
confirmed the ROS generation-mediated apoptotic cell death via caspase-3 and JNK activation.
These data were thus consistent with those from other studies highlighting the role of NADPH
Biomedicines 2018, 6, 39 14 of 28
oxidase-dependent generation of ROS leading to downstream JNK activation as a mechanism of
apoptosis induction by genipin. In light of comparative activity, genipin but not geniposide was able
to induce the above events when tested at 200 µM concentration [45]. The role of JNK1/2, ERK1/2,
and/or p38 MAPK following ROS generation could be dependent on the cell type and the type of
stimulus. In this regard, the various signal transduction pathways associated with ROS generation
induced by these drugs have already been described in the various cytotoxicity experiments listed
above. The further role of ROS in the mitochondria is discussed in the following Section 5.4.
Cancer cell killing via the upregulation of ROS production is closely linked to depletion of
antioxidant defenses. The diminished intracellular level of GSH is therefore the hallmark of cell
death induced by ROS-activating agents. Thus, drugs that deplete GSH, such as plant isothiocyanates
(e.g., moringin), do also have a potent anticancer effect [169]. Whether the α,β-unsaturated carbonyl
moiety in genipin/geniposide discussed in Section 4.1 directly interacts with sensitive thiol groups to
account for the diminished antioxidant (GSH) status remains to be proved.
5.4. Emerging Role of the Mitochondrial Uncoupling Protein-2 (UCP2) in Cancer Biology and Chemotherapy
With respect to the role of the mitochondria in orchestrating both cancer development and death
induced by a variety of agents, the uncoupling proteins (UCPs) have emerged as key players in recent
years. The basic process of cellular respiration and/or oxidative phosphorylation in the mitochondria
is based on the transport of protons (H+) out of the mitochondrial matrix to the intermembrane space.
The resulting mitochondrial membrane potential and protons electrochemical gradient drive ATP
synthase upon re-entry of protons. ATP generation in the mitochondria is therefore a result of the
coupling of the electron transport chain to ADP phosphorylation to form ATP (Figure 4). Located
at the inner mitochondrial membrane, the UCPs also transport protons back into the mitochondrial
matrix and hence abolish the proton gradient required for ATP production, but they also diminish
O2− production (reviewed in [170]). As cancer cells are under increased oxidative stress, they require
an increased activity of UCPs for their survival [171]. UCP2 is known to suppress mitochondrial ROS
production and is employed by drug-resistant cancer cells to mitigate oxidative stress [172–174]. Hence,
UCP2 is overexpressed in many cancer cells and plays a key role both in tumorigenesis and in cancer
progression. One of the emerging rational approaches in targeting cancer cells by chemotherapeutic
agents as well as in abolishing chemo-resistance is, thus, through UCP2 targeting. Once again,
the overall therapeutic principle is based on the fact that a higher mitochondrial membrane potential
means a higher level of ROS generation that could be overcome by the action of UPC2 as a natural
antioxidant in cancer cells. Recent studies also suggest that overexpressed UCP2 in cancer cells remove
Krebs-cycle metabolites from the mitochondria and hence shifts metabolic energy generation from
mitochondrial Krebs cycle/oxidative phosphorylation to oxygen-dependent glycolysis: a fundamental
process in cancer cells now widely known as the Warburg effect (Warburg, 1956) [175].
On the basis of the above discussion showing the critical role of UCP2 in cancer biology,
the reported effect of genipin and analogues on this system appears to constitute a major anticancer
mechanism of action. Mailloux et al. [176] studied the effect of genipin on UCP2 by using drug-sensitive
HL-60 cells and the drug-resistant MX2 subline as model systems. First, they showed that a higher
level of UCP2 could be detected in the mitochondria of drug-resistant cells, which appeared to account
for 37% of the resting cellular oxygen consumption. The resting cellular respiratory rates were also
higher in the drug-resistant cells. In the CHO cells stably expressing UCP2, genipin could suppress
this respiration by ~22% as compared to no effects in empty-vector CHO cells not expressing UCP2.
The increase in ROS by genipin was also shown to be linked to the inhibition of mitochondrial proton
leak induced by UCP2. A study by Ayyasamy et al. [177] was consistent with the above findings,
in that UCP2 was shown to be overexpressed in many cancer cell lines and to promote tumorigenic
properties both in vitro and in vivo. In this environment, genipin was shown to downregulate both
ROS and UCP2 function. The induction of apoptosis by genipin in pancreatic carcinoma cells (Panc-1)
was also established to be mediated through UCP2 inhibition and subsequent ROS production [178].
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A UCP2 inhibition-dependent mechanism of apoptosis induction in T47D breast cancer cells was
reported by Cho et al. implicating the reduction of both glycolytic flux and mitochondrial oxidative
respiration. [179]. A study by Yao et al. [179] was in support of the above finding, while a contradictory
result was reported in a study by Ma et al. [180], where upregulation of UCP2 expression in HepG2
cell lines of hepatocyte steatosis was reported. This could be related to the differential effects of
genipin at different doses, for example, in inducing or inhibiting the generation of ROS. Despite
this discrepancy, genipin is now widely employed as a standard UCP2-inhibiting drug in various
experimental models of ROS generation and in mitochondrial activity studies (e.g., [181–189] just to
mention few). Many other studies on cancer based on UCP2 inhibition and ROS generation by genipin
have also been published (e.g., [177,190,191]). The overall activity of genipin in this system is depicted
in Figure 4.
Figure 4. Targeting UCP2 by genipin in cancer. The electron transport chain in the mitochondria
comprises complexes I–IV that transfer electrons from NADH through a series of oxidation–reduction
reactions. The generation of the (H+) electrochemical gradient by the coordinated action of complexes
(I, II, and IV) allows coupling with phosphorylation via ATP synthase. In addition to O2 serving as
a final electron acceptor at complex IV, its premature reduction at complexes I and III could lead to O2−
formation. UCP2, which is excessively expressed in cancer cells, uncouples the process by creating
a (H+) leak and reducing the mitochondrial membrane potential. This mechanism, exploited by cancer
cells as a survival factor via reducing ROS generation, is targeted by genipin. CoQ, coenzyme Q and
Cyt C, cytochrome C.
The exact mechanism of action of genipin in inhibiting UPC2 is not known, but some clue on
structure-activity relationships has been outlined by Yang et al. [178]. As geniposide (discussed in
the previous section) is a weaker cytotoxic agent in vitro, and even 1-ethyl-genipin (ethyl insisted of
glucose (geniposide) derivative) failed to show cytotoxicity, the authors suggested a crucial role of
the free hydroxyl position both for cytotoxicity and UPC2 inhibition. Other derivatives, where the
10-hydroxyl position was derivatised (as acetate or trimethyl acyl) but still with the 1-OH hydroxyl
group intact, were also shown to be active. Further research is however required to clearly elucidate
the structure-activity relationship.
Readers should bear in mind that, while inhibiting UCP2 could offer a therapeutic option in cancer
cells, it could also be detrimental in some pathological conditions. For example, downregulation of
UCP2 by genipin was shown to exacerbate diabetes-induced kidney (proximal tubular cells) injury and
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apoptosis (Chen et al., 2014) [192]. Genipin could also exacerbate palmitate-induced hepatic steatosis
through UCP2 inhibition [193]. Even though genipin is known to have a reputed antidiabetic effect
(reviewed in [13]), its effect on UCP2 has been shown to be associated with reduced insulin-stimulated
glucose uptake in 3T3-L1 adipocytes [194]. On the other hand, its effect on UCP2-mediated proton
leak has been shown to reverse obesity- and high glucose-induced pancreatic beta cells [195].
6. Drug Potentiation
Through the effect related to UCP2 inhibition, Mailloux et al. [176] have shown that drug-resistant
leukemic cells could be sensitized to the cytotoxic action of menadione, doxorubicin, and epirubicin
when co-treated with genipin. Dando et al. [37] also studied the crosstalk between UCP2 inhibition
and the ROS/Akt/mechanistic target of rapamycin (mTOR) axis for genipin/everolimus anticancer
synergism. In their study, employing mice xenografts of pancreatic adenocarcinoma and in vitro
experiments, inhibition of UCP2 by genipin triggered the Akt/mTOR pathway by a ROS-dependent
mechanism. Tumour masses from mice injected with UCP2 (genipin) and mTOR inhibitors (everolimus)
revealed a strong reduction in tumour volume and number of mitosis, associated with a marked
cytosolic glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) nuclear positivity.
Their data appeared to reveal that genipin (200 µM) and everolimus could synergize in inhibiting cell
proliferation both in vitro and in vivo through GAPDH nuclear translocation. The potentiation effect of
genipin on anticancer agents in vitro via UCP2 inhibition and associated ROS generation has now been
established for various drugs, including for the cytotoxic effect of cisplatin in colon cancer cells [36],
breast cancer cells (MCF-7 and T47D) exposed to several chemotherapeutic agents [196], and various
pancreatic adenocarcinoma cell lines (PaCa44, PaCa3, Panc1, CFPAC1, T3M4, and MiaPaCa2) exposed
to gemcitabine [197].
Hauang et al. [198] have studied the potential potentiation effect of geniposide on doxorubicin
cytotoxicity in vitro by using drug-resistant human osteosarcoma (MG63/doxorubicin) tumour cells.
At a concentration that does not affect cancer cell growth, geniposide was shown to reverse doxorubicin
resistance in a dose-dependent manner. In MG63/DOX cancer cell-derived xenografts in nude mice,
geniposide also appeared to enhance the efficacy of doxorubicin. The effect of geniposide in this
potentiation was shown to be associated with the downregulation of P-glycoprotein expression.
A preliminary report by Su et al. [199] also showed an enhancement in the anticancer activity of
rapamycin by genipin.
Genipin was also shown to potentiate the cytotoxic effect of chemotherapeutic agents, such
as bortezomib, thalidomide, and paclitaxel in U266 cells [49]. On the other hand, by suppressing
oxidative stress and inflammation, genipin can also attenuate cisplatin-induced nephrotoxicity [200].
In a murine model of cisplatin-induced nephropathy, genipin pre-treatment was shown to alleviate
renal tissue injury by diminishing the serum blood urea nitrogen, creatinine, and cystatin C levels,
as well as those of kidney injury molecule-1. Furthermore, genipin could attenuate cisplatin-induced
oxidative/nitrative stress [200]. Hence, both the pro-oxidant and antioxidant effect of genipin
and related compounds could be exploited for cancer and numerous other pathological conditions.
Depending on concentrations/doses and cell types, variable outcomes could also be achieved.
7. General Summary and Conclusions
Plants are widely exploited natural sources of drugs for cancer therapy. While some of these
drugs have been identified through random screening programs, like taxanes, some resulted from
research on traditional medicinal uses, as exemplified by genipin and geniposide presented in this
review. The level of anticancer effect by genipin/geniposide in terms of potency does not match that
of taxanes or other mechanism-specific anticancer drugs, but their multiple mechanisms of action
and chemical characteristics appear to provide valuable lessons in advancing our knowledge in the
field. These compounds have a plethora of effects in cancer development (carcinogenesis), survival,
and metastasis that may be summarized as follow:
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• Anticarcinogenic effect via antioxidant and anti-inflammatory (e.g., Nrf2, GPx induction) mechanisms.
• Targeting specific enzymes (e.g., GGT, MMPs) involved in carcinogenesis.
• Modulation of signal transduction pathways (e.g., MAPK such as JNK, p38, and ERK; PI3K, Akt,
JAK1, etc.) involved in cell proliferation, inflammation, and cell death.
• Suppression of the production and function of proinflammatory cytokines (such as IL-1, IL-6,
and TNF-α) and other proteins (iNOS).
• Modulation of various transcription factors (Egr1, NF-κB, AP-1, p21, STAT3) involved in
inflammation and cancer biology and of transcriptional modulators such as SMAD2.
• Upregulation of genes/proteins that promote cell death and downregulation of survival
genes/proteins; p53, Bcl-2, Bcl-xL, survivin, c-Myc, Bax, etc. are classical examples.
• Enhancement od ROS formation both by the NADPH oxidase and UCP2 pathways (see Figure 5).
• Triggering of cell cycle arrest (G1/S phase or G2/M phase) by modulating cyclin-dependent kinases.
• Mechanism related to topoisomerase I poisoning for cytotoxicity and downregulation of
P-glycoprotein that allow drug potentiation and/or combination therapy.
• Activation of procaspases (e.g., procaspase-8 and 9) and caspases including the final apoptosis
executioner, caspase 3.
Figure 5. The dual effect of genipin/geniposide on ROS. The plus (+) sign indicates potentiation while
minus (−) sign indicates inhibition.
The most crucial effect of genipin/geniposide appears to be linked to the double-edge sword
mechanism of life and death balancing act by ROS and/or inflammation (Figure 5). They appear
to enhance ROS generation both through the NADPH oxidase system and via the mitochondria,
primarily through a UCP2 mechanism in cancer cells. This effect, particularly by genipin, supports
thier use as gold-standard reference compounds in cancer pharmacology studies. The same mechanism
involved in carcinogenesis is also targeted by genipin/geniposide, as evidenced from both in vitro
and in vivo data. Such an effect, perhaps obtainable even at smaller doses, appears to have a relevant
value for therapeutic approaches focused on the chemoprevention or nutraceutical utilization of
plant resources. In this connection, the common fruits of the plants yielding genipin/geniposide are
important resources to be taken into consideration. The demise of genipin/geniposide as anticancer
agents appears to lie on their dual prooxidant/antioxidant effect, with their overall anticancer effect
on established cancers appearing to be mediated at fairly large doses. Future studies are therefore
required to disentangle these conflicting pharmacological properties, perhaps through structural
design, to confer these compounds a far greater potency. In the meantime, the lessons learnt from
these compounds as anticancer agents, from their pharmacokinetics profiles to their mechanisms of
action, are further examples of the role played by plants as valuable sources of anticancer drugs.
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